189 related articles for article (PubMed ID: 17033167)
1. Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions.
Sharma BK; Smith CC; Laing JM; Rucker DA; Burnett JW; Aurelian L
Dermatology; 2006; 213(3):192-9. PubMed ID: 17033167
[TBL] [Abstract][Full Text] [Related]
2. ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma.
Guan X; Sagara J; Yokoyama T; Koganehira Y; Oguchi M; Saida T; Taniguchi S
Int J Cancer; 2003 Nov; 107(2):202-8. PubMed ID: 12949795
[TBL] [Abstract][Full Text] [Related]
3. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
4. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.
Björnhagen V; Bonfoco E; Brahme EM; Lindholm J; Auer G
Am J Dermatopathol; 1994 Dec; 16(6):615-23. PubMed ID: 7864299
[TBL] [Abstract][Full Text] [Related]
5. Expression of NM23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin.
Reichrath J; Seyfried P; Braun R; Müller SM; Baum HP; Bahmer FA
Dermatology; 1997; 194(2):136-9. PubMed ID: 9094461
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 27 is expressed in normal and malignant human melanocytes in vivo.
Kang SH; Fung MA; Gandour-Edwards R; Reilly D; Dizon T; Grahn J; Isseroff RR
J Cutan Pathol; 2004 Nov; 31(10):665-71. PubMed ID: 15491326
[TBL] [Abstract][Full Text] [Related]
7. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi.
Cerroni L; Soyer HP; Kerl H
Am J Dermatopathol; 1995 Feb; 17(1):7-11. PubMed ID: 7695015
[TBL] [Abstract][Full Text] [Related]
8. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
Skender-Kalnenas TM; English DR; Heenan PJ
J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.
Uribe P; Wistuba II; González S
Am J Dermatopathol; 2003 Oct; 25(5):365-70. PubMed ID: 14501284
[TBL] [Abstract][Full Text] [Related]
10. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
11. The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy.
Smith CC; Li B; Liu J; Lee KS; Aurelian L
Cancer Invest; 2011 Jul; 29(6):383-95. PubMed ID: 21649464
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
[TBL] [Abstract][Full Text] [Related]
13. A hypothesis incorporating the histologic characteristics of dysplastic nevi into the normal biological development of melanocytic nevi.
Piepkorn M
Arch Dermatol; 1990 Apr; 126(4):514-8. PubMed ID: 2321996
[TBL] [Abstract][Full Text] [Related]
14. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
15. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
16. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
18. Clinico-pathological impact of fibroplasia in melanocytic nevi: a critical revision of 209 cases.
Cesinaro AM
APMIS; 2012 Aug; 120(8):658-65. PubMed ID: 22779689
[TBL] [Abstract][Full Text] [Related]
19. The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers.
Quiohilag K; Caie P; Oniscu A; Brenn T; Harrison D
Virchows Arch; 2020 Jul; 477(1):121-130. PubMed ID: 32388720
[TBL] [Abstract][Full Text] [Related]
20. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
Touab M; Arumi-Uría M; Barranco C; Bassols A
Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]